Peak Actinium: The Complete Analysis
Q3 2026
The entire targeted alpha therapy sector agrees actinium-225 is the binding constraint. This report argues the belief is correct today and about to stop being correct, and dates the turn. Announced Ac-225 capacity is more than an order of magnitude above the historic baseline, and most of it lands around 2029, years before approvals and a treatment grid of a few hundred licensed sites can absorb it. In the 2029 to 2031 air-gap, clinical-grade supply exceeds absorbable demand and the scarcity premium compresses. The full edition dates that turn and maps where defensibility moves once volume stops being the moat: cost per curie, radionuclidic purity, and the licensed grid plus the people to run it.
Who reads this
Read by isotope-producer and radiopharma boards, the banks and funds underwriting alpha assets, and the corporate development teams pricing production capacity, across the US, UK, EU, and Canada.
Built from the ProGen Isotope Production Map and Clinical Trial Atlas, primary sources, and direct producer correspondence.
Authored by
Byron Fitzgerald, Founder, ProGen Search
What This Report Covers
Takes a single contrarian position, that the actinium-225 scarcity premium has an expiry date sooner than production-asset valuations assume, and stress-tests it from every angle, including the strongest arguments against it. It lands definite judgments on where the premium breaks, who is exposed, and what each stakeholder should do about it, while deliberately leaving open the question of which alpha isotope is stronger, because that trade-off is real in both directions.
Built on six findings: the supply wall is already booked and clusters on 2029; the demand that would absorb it is back-loaded behind a first approval no earlier than 2028; the two curves cross from the wrong side around 2029 to 2031; not all curies are the same product, because the Ac-227 impurity set by production route decides what clears a formulary; contracted demand is double-counted, because developers hedge across producers; and volume was never the moat. Every figure traces to a primary source or is flagged as a ProGen estimate. Where a number cannot be stood up, the report says so on the page rather than laundering it into apparent fact.
Buy this report
From
$1,495
Three licence tiers for individuals, teams, and institutions.
Individual
Single reader
$1,495
Enterprise
One operating company
$5,995
Investor & Bank Licence
Banks and institutional investors
$14,995
Chapters
Part I - The Consensus and the Turn
Why the sector settled on actinium-225 as the binding constraint, the close to $8bn of alpha M&A underwritten on that belief, and the thesis that the scarcity trade has an expiry date the market has not yet dated.
Part II - The Supply Wall
The complete producer grid classified by production route and Ac-227 liability with a ProGen delivery-confidence rating, the purity split that decides what clears a formulary, and the feedstock ceiling that could keep scarcity alive.
Part III - The Demand Curve
Twenty-three clinical-stage programmes and zero approvals, the absorbable-demand model across three approval-timing scenarios, the Authorized-User and site-capacity throttle, and the double-count that inflates contracted demand.
Part IV - The Crossover and the New Basis of Competition
Where and when the curves cross, the 2029 to 2031 air-gap, the cost-per-curie comparison after volume stops being scarce, and where defensibility moves once nameplate capacity is no longer the moat.
Part V - The Adjacencies
Ac-225 set against lead-212 and the other alphas as a structural trade-off rather than a verdict, and the read-through to the lutetium-177 scarcity episode the modality has already run once.
Part VI - Stakeholder Playbooks and Decision Tools
The investor exposure read across the strategics, the specialist capital and the public names, decision checklists for each stakeholder, and seven early indicators that the scarcity premium has begun to break.
Part VII - Scenarios, Risk and Outlook
The year-by-year outlook from 2026 to 2032, the strongest case against the thesis stated in full, and the two falsifiers that would prove the report wrong.
Appendices - The Data Room
The complete Ac-225 producer grid, the clinical programme register, the supply-agreement and double-count matrix, the alpha M&A and financing tracker, and the methodology, sourcing and glossary.
From the report
$8bn
of alpha-focused M&A has been underwritten on the belief that actinium-225 is the binding constraint. The belief is correct today, and about to stop being correct.
Announced Ac-225 capacity is more than an order of magnitude above the historic baseline, and most of it lands around 2029, into an approved, Authorized-User-gated demand base that regulation and the treatment grid keep small until after 2030. Supply crosses absorbable demand from the wrong side, and the scarcity premium, a forward price, begins compressing before the wall physically arrives.
Who reads this and what they use it for
Investors in production assets
Position over market size. Whether the asset is underwritten against three or more credible clean-route producers or on scarce access, the clean cost-per-curie it achieves at commercial utilisation, and whether it owns or only rents supply, purity, and grid reach.
Producers and CDMOs
Route over nameplate. Whether your route is clean or carries the Ac-227 liability, whether feedstock is secured rather than assumed, your cost-per-curie at 40, 70, and 90 percent utilisation, and whether you hold drug-product and delivery-grid reach or only isotope.
Developers
Supply security is close to solved, so the live questions are how many redundant hedges you carry and what they cost once scarcity fades, whether your isotope is clean-route to clear formulary review, and whether your model assumes incidence-based TAM or site-gated absorbable demand.
Hospitals and health systems
The grid is leverage. Whether you are one of the few hundred sites licensed to deliver alpha therapy, how you price the Ac-227 decommissioning exposure of each supply source, and whether your Authorized-User pipeline and alpha-specific licences are built ahead of demand.
Byron Fitzgerald, Founder, ProGen Search
About the Author
Byron Fitzgerald
Byron Fitzgerald has spent more than 15 years in life sciences executive search and founded ProGen Search in 2024. He is a three-time founder, having previously bootstrapped a specialist consultancy from a standing start to 36 consultants. He has placed VP to C-suite leadership across Quality, MSAT, Technical Operations, CMC, Manufacturing, Regulatory, and Business Development functions for organisations ranging from pre-clinical biotechs to multinational CDMOs and radiopharma developers. Through retained search and commissioned intelligence work, he speaks daily with the C-suite, investors, PE/VC partners, and BD leaders who set strategy across this sector.
His published market intelligence on radiopharmaceutical manufacturing, CDMO capacity constraints, ADC execution risk, and advanced modality talent markets is read by C-suite leaders, institutional investors, and board members globally.
Choose your access
Three tiers, calibrated to how you intend to use the work.
Individual
$1,495
Single reader. Personal use within one company.
- Single named reader licence
- Full PDF report (19 sections, all exhibits and appendices)
- The complete Ac-225 producer grid, classified by route and Ac-227 liability
- Direct email access to Byron Fitzgerald for clarification questions
Enterprise
$5,995
Distribute across one operating company or strategy team.
- Full company licence covering all employees and majority-owned subsidiaries
- Full PDF report (19 sections, all exhibits and appendices)
- The producer grid, the purity-adjusted supply model, and the supply-agreement matrix
- Internal redistribution rights (intranet, shared drives, board packs)
- Priority email access to Byron Fitzgerald
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
Investor & Bank Licence
$14,995
Investment banks, institutional investors, and consulting firms citing the report in client materials.
- Full firm licence covering all investment professionals, analysts, and portfolio companies
- Full PDF report (19 sections, all exhibits and appendices)
- The 90-fund investor exposure map and the seven early indicators
- Use in investor memos, client deliverables, due diligence reports, and committee papers
- Priority email access to Byron Fitzgerald
Need to pay by invoice or PO? Email byron.fitzgerald@progensearch.com.
By completing your purchase, you agree to our Purchase Terms.
Frequently asked questions
When and how do I get the report?
Every licensed copy is prepared and sent personally, direct by email, within 24 hours of purchase to the address you use at checkout. If you need a VAT invoice or have procurement requirements, reply to that email and it reaches Byron Fitzgerald directly, not a support queue.
What is the methodology and how is it sourced?
The report is built from the ProGen Isotope Production Map and Clinical Trial Atlas, primary sources, and in several load-bearing cases direct correspondence with producers, cross-checked against company disclosures and reputable trade press. Capacity figures are company-stated targets, not audited throughput, and are labelled as such. Where a number is a ProGen estimate or unverifiable in the public record, the report says so in the text rather than presenting it as fact.
What is the refund policy?
Purchases are non-refundable once the report has been sent. Because it is a licensed digital product prepared and delivered to you personally, by completing your purchase you agree that the licence is granted on delivery and that any cancellation or cooling-off right which would otherwise apply is waived to the fullest extent permitted by applicable law.
How do the licence tiers work?
The Individual licence is for a single named reader within one company. The Enterprise licence covers unlimited internal seats inside one operating entity, including internal redistribution and excerpting. The Investor and Bank licence extends those rights to multiple funds, teams, portfolio companies, and citation in client-facing materials, with attribution to ProGen Search.
How does this relate to the other ProGen radiopharma reports?
Peak Actinium is the flagship of the radiopharma premium line and draws directly on The State of Radiopharmaceuticals 2026, The Isotope Production Map Q2 2026, and The Radiopharma Capacity Crunch. Those map the sector, the physical isotope infrastructure, and the clinical-versus-manufacturing constraint. Peak Actinium takes the single question of the actinium-225 scarcity premium and dates when it breaks. They stand alone and read well together.
Free Radiopharma intelligence
Read The Radiopharma Capacity Crunch Q2 2026 and The 120-Day Line in the Intelligence Vault. Visit Vault →
Ready when you are.
If you are pricing an actinium-225 production asset, planning capacity, underwriting an alpha deal, or building a treatment network, the question to carry into the next board meeting is whether the asset is underwritten against a third and fourth credible producer, or still priced as though the molecule is the moat. This report answers it.
View pricingWant ongoing intelligence between flagship reports? ProGen Radar Pro - $99/month, 14-day guarantee. Learn more →